Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454502 | 0.88 | ROCK2 (0.56) | ROCK2ROCK1MAPK14CHEK1PARP1 | |
| SCHEMBL19902479 | 0.81 | KHK (0.48) | ROCK2MAPK14 | |
| SCHEMBL19902585 | 0.80 | CHEK1 (0.47) | ROCK2MAPK14CHEK1SMYD3MEN1 | |
| SCHEMBL19902622 | 0.80 | MAPK14 (0.54) | ROCK2MAPK14CHEK1CFTR | |
| SCHEMBL19902696 | 0.80 | NPC1 (0.50) | ROCK2ROCK1CHEK1SMYD3MEN1 | |
| SCHEMBL19902501 | 0.80 | PTGER3 (0.47) | ROCK2MAPK14MAOB | |
| SCHEMBL19902640 | 0.79 | ROCK2 (0.48) | ROCK2ROCK1SMYD3MEN1NPC1 | |
| SCHEMBL20229915 | 0.79 | ROCK2 (0.51) | ROCK2ROCK1MAPK14 | |
| SCHEMBL19902707 | 0.79 | KDM5A (0.49) | ROCK2MAPK14CHEK1 | |
| SCHEMBL19902383 | 0.78 | CYP1A2 (0.48) | ROCK2MAPK14SMYD3MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK2 3/4885ROCK1 1/4885MAPK14 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.